WO2002000825A3 - Nouveau polypeptide, antigene stromal proteique nucleaire 110.34, et polynucleotide codant ce polypeptide - Google Patents
Nouveau polypeptide, antigene stromal proteique nucleaire 110.34, et polynucleotide codant ce polypeptide Download PDFInfo
- Publication number
- WO2002000825A3 WO2002000825A3 PCT/CN2001/000941 CN0100941W WO0200825A3 WO 2002000825 A3 WO2002000825 A3 WO 2002000825A3 CN 0100941 W CN0100941 W CN 0100941W WO 0200825 A3 WO0200825 A3 WO 0200825A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- antigene
- polynucleotide encoding
- receptor protein
- nuclear receptor
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 108020005497 Nuclear hormone receptor Proteins 0.000 title abstract 3
- 108020004017 nuclear receptors Proteins 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 title 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 2
- 206010012559 Developmental delay Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un nouveau polypeptide, un antigène stromal protéique nucléaire 110.34, et un polynucléotide codant ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment de l'hémopathie, de toutes sortes de tumeurs, des troubles du développement, d'inflammations et de maladies immunitaires. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant l'antigène stromal protéique nucléaire 110.34.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU93610/01A AU9361001A (en) | 2000-06-12 | 2001-06-11 | A novel polypeptide, a nuclear receptor protein stromal antigene 110.34 and the polynucleotide encoding the polypeptide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00116420A CN1327987A (zh) | 2000-06-12 | 2000-06-12 | 一种新的多肽——核蛋白基质抗原110.34和编码这种多肽的多核苷酸 |
| CN00116420.1 | 2000-06-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002000825A2 WO2002000825A2 (fr) | 2002-01-03 |
| WO2002000825A3 true WO2002000825A3 (fr) | 2002-05-02 |
Family
ID=4585824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2001/000941 WO2002000825A2 (fr) | 2000-06-12 | 2001-06-11 | Nouveau polypeptide, antigene stromal proteique nucleaire 110.34, et polynucleotide codant ce polypeptide |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1327987A (fr) |
| AU (1) | AU9361001A (fr) |
| WO (1) | WO2002000825A2 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316910A (en) * | 1991-03-19 | 1994-05-31 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bioassay for influenza A and B nucleoprotein |
-
2000
- 2000-06-12 CN CN00116420A patent/CN1327987A/zh active Pending
-
2001
- 2001-06-11 AU AU93610/01A patent/AU9361001A/en not_active Abandoned
- 2001-06-11 WO PCT/CN2001/000941 patent/WO2002000825A2/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316910A (en) * | 1991-03-19 | 1994-05-31 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bioassay for influenza A and B nucleoprotein |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002000825A2 (fr) | 2002-01-03 |
| AU9361001A (en) | 2002-01-08 |
| CN1327987A (zh) | 2001-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001083688A3 (fr) | Nouveau polypeptide, sous-unite humaine 13 phosphatidylinositol-4-phosphate-5-kinase ii beta, et polynucleotide codant pour ce polypeptide | |
| WO2002000825A3 (fr) | Nouveau polypeptide, antigene stromal proteique nucleaire 110.34, et polynucleotide codant ce polypeptide | |
| WO2002000822A3 (fr) | Nouveau polypeptide, sous-unite humaine 2 $g(b) 16.5 du facteur d'initiation necessaire a la synthese proteique, et polynucleotide codant ce polypeptide | |
| WO2002000826A3 (fr) | Nouveau polypeptide, proteine humaine de methylation d'adn, et polynucleotide codant ce polypeptide | |
| WO2001096525A3 (fr) | Nouveau polypeptide, unite de transposition pogo 18, et polynucleotide codant ce polypeptide | |
| WO2001075023A3 (fr) | Nouveau polypeptide, phosphatidylinositol-3 (ptdins 3) kinase humaine 9, et polynucleotide codant pour ce polypeptide | |
| WO2001079439A3 (fr) | Nouveau polypeptide, proteine humaine de reception cannabinoide 19, et un polynucleotide codant pour ce polypeptide | |
| WO2001075054A3 (fr) | Nouveau polypeptide, facteur humain de regulation 30 de la transcription de la microglobuline, et polynucleotide codant pour ce polypeptide | |
| WO2001075025A3 (fr) | Nouveau polypeptide, thyroglobuline humaine 9, et polynucleotide codant pour ce polypeptide | |
| WO2001075053A3 (fr) | Nouveau polypeptide, chaperonine humaine 14, et polynucleotide codant pour ce polypeptide | |
| WO2001081536A3 (fr) | Nouveau polypeptide, proteine kinase ysk1 humaine 10, et polynucleotide codant pour ce polypeptide | |
| WO2002000824A3 (fr) | Nouveau polypeptide, proteine humaine 10.56 du gene cancerigene tre, et polynucleotide codant ce polypeptide | |
| WO2001075014A3 (fr) | Nouveau polypeptide, phosphatidylinositol-3 (ptdins 3) kinase 35 humaine, et polynucleotide codant pour ce polypeptide | |
| WO2001083685A3 (fr) | Nouveau polypeptide, proteine cap 10, et polynucleotide codant pour ce polypeptide | |
| WO2001075029A3 (fr) | Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide | |
| WO2002008421A1 (fr) | Nouveau polypeptide, recepteur humain 21.45 du facteur de la necrose tumorale, et polynucleotide codant ce polypeptide | |
| WO2001075036A3 (fr) | Nouveau polypeptide, immunophiline humaine 14, et polynucleotide codant pour ce polypeptide | |
| WO2001075024A3 (fr) | Nouveau polypeptide, facteur humain 13 associe a nf-e2, et polynucleotide codant pour ce polypeptide | |
| WO2001075011A3 (fr) | Nouveau polypeptide, proteine humaine de constitution 10 de cytochromes, et polynucleotide codant pour ce polypeptide | |
| WO2001075062A3 (fr) | Nouveau polypeptide, hydrogenase humaine 10, et polynucleotide codant pour ce polypeptide | |
| WO2001081537A3 (fr) | Nouveau polypeptide, sous-unite 49 humaine du facteur c(a1) 37kd de replication de l'adn, et polynucleotide codant pour ce polypeptide | |
| WO2001075010A3 (fr) | Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide | |
| WO2002000827A3 (fr) | Nouveau polypeptide, proteine de methylation d'adn-cysteine methyl-transferase 10, et polynucleotide codant ce polypeptide | |
| WO2001075043A3 (fr) | Nouveau polypeptide, proteine kinase humaine 9 adn-dependante, et polynucleotide codant pour ce polypeptide | |
| WO2001083684A3 (fr) | Nouveau polypeptide, proteine humaine krab kraz2-12 a doigt de zinc, et polynucleotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |